Cue Biopharma Acquires Dual-Mechanism Anti-IgE Asset in $700M Deal
Event summary
- Cue Biopharma licensed Ascendant Health’s Ascendant-221, a Phase 2 clinical-stage anti-IgE antibody, for global rights excluding China.
- The deal includes a $15 million upfront payment and up to $676.5 million in milestone payments, totaling a potential $700 million.
- Ascendant-221 is currently in a Phase 2 trial in China for chronic spontaneous urticaria (CSU), with results expected in 2H 2026.
- Cue Biopharma plans to initiate a global Phase 2b trial in food allergy following the CSU data review.
The big picture
Cue Biopharma’s acquisition of Ascendant-221 represents a strategic pivot towards becoming a clinical-stage company with a more diverse pipeline. The $700 million potential deal underscores the continued investor interest in allergy therapies, a market valued at billions annually. This move also signals a shift away from Cue’s Immuno-STAT platform, potentially indicating a reassessment of its long-term viability.
What we're watching
- Clinical Data
- The results of the ongoing Phase 2 trial in China for CSU will be critical in determining the viability of Ascendant-221 and influencing Cue Biopharma’s Phase 2b food allergy trial design.
- Financial Impact
- Cue Biopharma’s ability to achieve the milestone payments tied to Ascendant-221’s development and commercialization will significantly impact its financial performance and burn rate.
- Competitive Landscape
- How Ascendant-221’s dual mechanism of action performs relative to existing IgE therapies, particularly Dupilumab, will dictate its market share and potential for best-in-class status.
Related topics